Selection and growth regulation of genetically modified cells with hapten-specific antibody/receptor tyrosine kinase chimera

Biotechnology Progress

Volumn 25, Issue 4, 2009, Pages 1138-1145

  Tanaka, Kento ^a   Kawahara, Masahiro ^a   Ueda, Hiroshi ^a   Nagamune, Teruyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antibody; Growth control; Mammalian cell; Receptor tyrosine kinase; Signal transduction

Indexed keywords

ANTI-FLUORESCEIN; ANTIBODY FRAGMENT; CELL AMPLIFICATION; CHIMERIC RECEPTORS; COGNATE ANTIGENS; EPIDERMAL GROWTH FACTOR RECEPTORS; ERYTHROPOIETIN RECEPTORS; EXTRACELLULAR; EXTRACELLULAR DOMAINS; GENETICALLY MODIFIED; GROWTH CONTROL; GROWTH REGULATION; HEMATOPOIETIC CELL; HEMATOPOIETIC CELL LINE; MAMMALIAN CELL; OVER-EXPRESSION; RECEPTOR CHIMERA; RECEPTOR TYROSINE KINASE; SIGNALING MOLECULES; SINGLE-CHAIN FV; TUMORIGENESIS; TYROSINE KINASE; WILD TYPES;

AMINO ACIDS; AMPLIFICATION; ANTIBODIES; ANTIGENS; BACTERIOPHAGES; BODY FLUIDS; CELL CULTURE; CELL PROLIFERATION; MAMMALS; SIGNAL TRANSDUCTION;

CELL MEMBRANES;

ERYTHROPOIETIN RECEPTOR; HAPTEN; HYBRID PROTEIN; PROTEIN TYROSINE KINASE;

ANIMAL; CELL LINE; CELL PROLIFERATION; CONFERENCE PAPER; CYTOLOGY; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOGLOBULIN VARIABLE REGION; METABOLISM; MOUSE; PROTEIN ENGINEERING; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; CELL PROLIFERATION; HAPTENS; HEMATOPOIETIC STEM CELLS; IMMUNOGLOBULIN VARIABLE REGION; MICE; PROTEIN ENGINEERING; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 69149095021     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1002/btpr.185     Document Type: Conference Paper

References (32)

1. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000; 103: 211-225.
2. Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta. 2007; 1773: 1161-1176.
3. Hubbard SR. Structural analysis of receptor tyrosine kinases. Prog Biophys Mol Biol. 1999; 71: 343-358.
4. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004; 4: 361-370. (Pubitemid 38579482)
5. Roskoski R J.r. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochim Biophys Acta. 2004; 319: 1-11.
6. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim J, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 2002; 110: 775-787.
7. Dawson JP, Berger MB, Lin C, Schlessinger J, Lemmon MA, Ferguson KM. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Biol Cell. 2005; 25: 7734-7742.
8. Bell CA, Tynan JA, Hart KC, Meyar AN, Robertson SC, Donoghue DJ. Rotational coupling of the transmembrane and kinase domains of Neu receptor tyrosine kinase. Mol Biol Cell. 2000; 11: 3589-3599.
9. Webb SE, Pollard JW, Jones GE. Direct observation and quantification of macrophage chemoattraction to the growth factor CSF-1. J Cell Sci. 1996; 109: 793-803.
10. Ohashi H, Maruyama K, Liu Y, Yoshimura A. Ligand-induced activation of chimeric receptors between the erythropoietin receptor and receptor tyrosine kinases. Proc Natl Acad Sci USA. 1994; 91: 158-162.
11. Roussel MF, Transy C, Kato J, Reinherz EL, Sherr CJ. Antibody-induced mitogenecity mediated by a chimeric CD2-c-fms receptor. Mol Biol Cell. 1990; 10: 2407-2412.
12. Stry MV, Kazlauskas A, Schreiber SL, Symes K. Distinct effectors of platelet-derived growth factor receptor-alpha signaling are required for cell survival during embryogenesis. Proc Natl Acad Sci USA. 2005; 102: 8233-8238.
13. Li Z, Otto K, Richard RE, Ni S, Kirillova I, Fausto N, Blau CA, Lieber A. Dimerizer-induced proliferation of genetically modified hepatocytes. Mol Ther. 2002; 5: 420-426.
14. Yang J, Symes K, Mercola M, Schreiber SL. Small-molecule control of insulin and PDGF receptor signaling and the role of membrane attachment. Curr Biol. 1997; 8: 11-18.
15. Berger C, Blau CA, Huang M, Luliucci JD, Dalgarno DC, Gaschet J, Heimfeld S, Clackson T, Riddell SR. Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood. 2004; 103: 1261-1269.
16. Gazdoiu S, Yamoah K, Wu K, Escalante CR, Tappin I, Bermudez V, Aggarwal AK, Hurwitz J, Pan Z. Proximity-induced activation of human Cdc34 through heterologous dimerization. Proc Natl Acad Sci USA. 2005; 102: 15053-15058.
17. Quintarelli C, Vera J, Savoldo B, Atianese GMPG, Pule M, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Coexpression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007; 10: 2793-2802.
18. Mallet VO, Mitchell C, Guidotti JE, Jaffray P, Fabre M, Spencer D, Arnoult D, Kahn A, Gilgenkrantz H. Conditinal cell ablation by tight control of caspase-3 dimerization in transgenic mice. Nat Biotechnol. 2002; 20: 1234-1239.
19. Ueda H, Kawahara M, Aburatani T, Tsumoto K, Todokoro K, Suzuki E, Nishimura H, Schueler PA, Winter G, Mahoney WC, Kumagai I, Nagamune T. Cell-growth control by monomeric antigen; the cell surface expression of lysozyme-specific Ig V-domains fused to truncated Epo receptor. J Immunol Methods. 2000; 241: 159-170.
20. Kawahara M, Ueda H, Morita S, Tsumoto K, Kumagai I, Nagamune T. Bypassing antibiotic selection: positive screening of genetically modified cells with an antigen-dependent proliferation switch. Nucleic Acids Res. 2003; 31: e32.
21. Sogo T, Kawahara M, Tsumoto K, Kumagai I, Ueda H, Nagamune T. Selective expansion of genetically modified T cells using an antibody/interleukin-2 receptor chimera. J Immunol Methods. 2008; 337: 16-23.
22. Kawahara M, Kimura H, Ueda H, Nagamune T. Selection of genetically modified cell population using hapten-specific antibody/receptor chimera. Biochem Biophys Res Commun. 2004; 315: 132-138.
23. de Larco JE, Todaro GJ. Epithelioid and fibroblastic rat kidney cell clones: epidermal growth factor (EGF) receptors and the effect of mouse sarcoma virus transformation. J Cell Physiol. 1978; 94: 335-342.
24. Sherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look AT, Stanley ER. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell. 1985; 41: 665-676.
25. Palacios R, Steinmetz M. Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell. 1985; 41: 727-734.
26. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000; 7: 1063-1066.
27. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005; 65: 7096-7101.
28. Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgessa AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003; 284: 31-53.
29. Pixley FJ, Stanley ER. CSF1 regulation of wandering macrophage: complexity in action. Trends Cell Biol. 2004; 14: 628-638.
30. Dawson JP, Bu Z, Lemmon MA. Ligand-induced structural transitions in ErbB receptor extracellular domains. Structure. 2007; 15: 942-954.
31. Mendrola JM, Berger MB, King MC, Lemmon MA. The single transmembrane domains of ErbB receptors self-associate in cell membranes. J Biol Chem. 2002; 277: 4704-4712.
32. Nakaji-Hirabayashi T, Kato K, Arima Y, Iwata H. Multifunctional chimeric proteins for the sequential regulation of neural stem cell differentiation. Bioconj Chem. 2008; 19: 516-524.